- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02479087
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients (ITI)
IMMUNE TOLERANCE INDUCTION, BY FACTOR VIII CONCENTRATE CONTAINING VON WILLEBRAND FACTOR, IN SEVERE OR MODERATE HAEMOPHILIA A PATIENTS WITH INHIBITORS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Pier Mannuccio Mannucci, MD
- Phone Number: +39 0255038377
- Email: piermannuccio.mannucci@unimi.it
Study Contact Backup
- Name: Elena Santagostino, MD
- Phone Number: +39 0255035273
- Email: elena.santagostino@policlinico.mi.it
Study Locations
-
-
-
Cairo, Egypt
- Not yet recruiting
- Ain Shams Pediatric hospital, Ain Shams University
-
Contact:
- Mohssen El-Alfy, MD
- Phone Number: +20 1000864343
- Email: elalfym@hotmail.com
-
Contact:
- Shereen Abdel Ghany, MD
- Phone Number: +20 1200533484
- Email: shereen22eg@yahoo.com
-
Principal Investigator:
- Mohssen El-Alfy, MD
-
Sub-Investigator:
- Shereen Abdel Ghany, MD
-
Sub-Investigator:
- Neveen Gamal, MD
-
Cairo, Egypt
- Not yet recruiting
- Almoneera Pediatric Cairo University Hospital (Abu El- Reesh)
-
Contact:
- Amal El-Beshlawy, MD
- Phone Number: +20 1223124674
- Email: amalelbeshlawy@yahoo.com
-
Contact:
- Sonia Aldof, MD
- Phone Number: +20 1223431046
- Email: sonia_adolf@yahoo.com
-
Principal Investigator:
- Amal El-Beshlawy, MD
-
Sub-Investigator:
- Sonia Aldof, MD
-
Sub-Investigator:
- Shaymaa Mohamed, MD
-
-
-
-
-
Bangalore, India, 560034
- Recruiting
- St. John's Medical College Hospital
-
Contact:
- Cecil Ross, MD
- Phone Number: +91 9448493705
- Email: cecilross@bsnl.in
-
Contact:
- Sita Lakshmi, MD
- Phone Number: +91 8022065178
- Email: slvbs@yahoo.co.in
-
Sub-Investigator:
- Sita Lakshmi, MD
-
Sub-Investigator:
- Fulton D'souza, MD
-
New Delhi, India, 110029
- Recruiting
- All India Institute of Medical Sciences
-
Contact:
- Tulika Seth, MD
- Phone Number: +91 9868397236
- Email: tuliseth@yahoo.com
-
Contact:
- Renu Saxena, MD
- Phone Number: +91 1126594670
- Email: renusax@hotmail.com
-
Sub-Investigator:
- Renu Saxena, MD
-
Sub-Investigator:
- Vandana Sharma, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects (his/her parent/legal representative), must have given a written informed consent.
- Male children: age <12 years.
- Severe or moderate Haemophilia A (FVIII <2%).
- High responders (clinical history of inhibitor peak > 5BU) or low-responders (clinical history of inhibitor peak < 5 BU) with potential bleedings, assessed by responsible physicians as not to be treated with high FVIII doses.
- Any level of inhibitor at study enrollment.
- Willingness and ability to participate in the study.
- No other experimental treatments (involving or not FVIII concentrates).
Exclusion Criteria:
- Any clinically relevant abnormality, in hematological, biochemical and urinary routine examinations, or any condition or treatment which in the investigator's opinion, makes the patient not eligible for the study.
- Intolerance to active substances or to any of the excipients of FVIII / VWF concentrates.
- Concomitant systemic treatment with immunosuppressive drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Plasma-derived FVIII/VWF concentrate
The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day. This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables. The initial dosage can be then adjusted on the base of response. |
The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5. The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein. The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy: evaluation of the success of IT induction
Time Frame: Up to33 months
|
Success:Inhibitor disappearance/reduction to <0.6 BU/ml with FVIII activity recovery of at least ≥ 66% within 33 months of treatment ; Partial Success: inhibitor reduction to <5 BU/ml with clinical response to FVIII treatment, not followed by an inhibitor increase to values >5 BU/ml for a treatment period of 6 months on demand, or for 12 months of prophylactic treatment; No Response (Failure):Failure in relation to the above criteria defining complete response and partial response within 33 months, OR a reduction of the concentration of the inhibitor, less than 20%, compared to the peak of inhibitor in the IT, in every period of 6 months after the first 3 months of treatment.
This implies that 9 months represents the minimum period of treatment and 33 months the maximum possible duration of ITI without success, OR patient withdrawal from the study for any reason.
|
Up to33 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (adverse events)
Time Frame: Up to 33 months
|
Description and incidence of adverse events during the course of prophylactic treatment, with severity, correlation with the investigational product and final outcome.
|
Up to 33 months
|
Analysis of treatment compliance
Time Frame: Up to 33 months
|
Description of the patient's adherence to the optimal prolonged treatment.
|
Up to 33 months
|
Efficacy evaluation - Time to achieve ITI
Time Frame: Up to 33 months
|
Time to achieve the complete or partial response (as defined in the primary outcome measure).
|
Up to 33 months
|
Evaluation of the cost of therapy
Time Frame: Up to 33 months
|
Recording of overall amount of direct costs of therapy.
|
Up to 33 months
|
Efficacy evaluation - IT persistence
Time Frame: Up to 33 months+ 12 months FU
|
Absence of relapse, assessed at 12 months from IT achievement
|
Up to 33 months+ 12 months FU
|
Efficacy evaluation - FVIII genetic defect role in IT achievement
Time Frame: Up to 33 months
|
Role of FVIII mutations in influencing IT achievement
|
Up to 33 months
|
Efficacy evaluation - Role of an immediate IT to delayed IT in IT induction.
Time Frame: Up to 33 months
|
Time elapsing between the onset of the inhibitor and the beginning of treatment and its importance for induction of IT in achieving primary endpoints.
|
Up to 33 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Pier Mannuccio Mannucci, MD, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
- Study Director: Flora Peyvandi, MD, Università di Milano, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
- Study Director: Elena Santagostino, MD, Centro Emofilia e Trombosi Angela Bianchi Bonomi, IRCCS Fondazione Ospedale Maggiore Policlinico
Publications and helpful links
General Publications
- Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia. 1996 Apr;2(2):95-9. doi: 10.1111/j.1365-2516.1996.tb00022.x.
- Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007 Jul;13(4):373-9. doi: 10.1111/j.1365-2516.2007.01484.x.
- Gilles JG, Saint-Remy JMR. Recombinant and plasma-derived factor VIII are immunologically distinct in in vitro assays. Thromb Haemost 1995; 73:1213.
- Guerois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Negrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost. 1995 Feb;73(2):215-8.
- Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost. 1997 Sep;78(3):1027-9.
- Teitel JM. Safety of coagulation factor concentrates. Haemophilia. 1998 Jul;4(4):393-401. doi: 10.1046/j.1365-2516.1998.440393.x.
- Rokicka-Milewska R, Klukowska A, Dreger B, Beer H-J. Incidence of factor VIII inhibitor development in previously untreated Haemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Ann Hematol 1999; 78 (suppl 1)
- Aznar JA, Lorenzo JI, Molina R, Haya S, Querol F, Dasi MA. Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Haemophilia. 1998 Jan;4(1):21-4. doi: 10.1046/j.1365-2516.1998.00139.x.
- Smith MP, Rice KM, Savidge GF. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment. Thromb Haemost. 1997 Feb;77(2):406-7. No abstract available.
- Sukhu K, Keeling DM, Giangrande PL. Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clin Lab Haematol. 2000 Oct;22(5):287-90. doi: 10.1046/j.1365-2257.2000.00328.x.
- Gensana M, Altisent C, Aznar JA, Casana P, Hernandez F, Jorquera JI, Magallon M, Massot M, Puig L. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001 Jul;7(4):369-74. doi: 10.1046/j.1365-2516.2001.00526.x.
- Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost. 1996 Nov;76(5):749-54.
- Kreutz W: Immune tolerance induction (ITI) in Haemophilia A-patients with inhibitors - the choice of concentrate affecting success. Haematologica 2001; 86 (S4):16-20
- Kreuz W, Steiner J, Auerswald G, Beeg T, Becker S. Successful immunetolerance therapy of FVIII-inhibitor in chldren after changing from high to intermediate purity FVIII concentrate. Ann Hematol 1996; 72 (suppl 1).
- Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005 Sep;90(9):1288-90.
- Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995 Aug 1;86(3):983-8.
- Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18.
- Haya S, Casaña P, Moret A, Cid RA, Cabrera N, Abad L, Aznar AJ. Immunotolerance Induction Treatments in Hemophilia. J.of Coagulation Disorders 2009; 1(1): 37-42.
- Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 2000 Sep 1;96(5):1698-702.
- Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010 Sep;150(5):515-28. doi: 10.1111/j.1365-2141.2010.08263.x. Epub 2010 Jun 22.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FCG-CNS-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Korea, Republic of, Brazil, Italy
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on Plasma-derived FVIII/VWF concentrate
-
Grifols Therapeutics LLCInstituto Grifols, S.A.Recruiting
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseUnited States, Germany, United Kingdom, Italy, Austria, Canada
-
OctapharmaCompletedPrevent Bleeding in Major SurgeryUnited States, Turkey, Romania, India, Bulgaria, Italy, Oman, Poland, South Africa
-
Skane University HospitalCSL Behring; VersitiCompletedVon Willebrand DiseaseUnited States, Sweden
-
Grifols Therapeutics LLCInstituto Grifols, S.A.CompletedCongenital AfibrinogenemiaIndia, United States, Italy, Lebanon
-
OctapharmaCompletedCongenital Fibrinogen Deficiency | AfibrinogenemiaIran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlActive, not recruitingType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlCompletedHemophilia AUnited States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
-
Grifols Biologicals, LLCActive, not recruitingAntithrombin III Deficiency
-
The University of Texas Health Science Center,...Baxter Healthcare Corporation; Rho, Inc.CompletedHemophilia AUnited States, Austria, Italy, Netherlands, Sweden